About Celltrion
Celltrion is a company based in Incheon (South Korea) founded in 2002. The company has 2,900 employees as of December 31, 2024. Celltrion has completed 1 acquisition, including iQone Healthcare Group. Celltrion offers products and services including Biosimilars and R&D Services.
- Headquarter Incheon, South Korea
- Employees 2900 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Celltrion, Inc.
-
Annual Revenue
$2.41 B (USD)63.45as on Dec 31, 2024
-
Net Profit
$286.61 M (USD)-21.09as on Dec 31, 2024
-
EBITDA
$617.22 M (USD)1.47as on Dec 31, 2024
-
Latest Funding Round
Not available
- Investors
-
Employee Count
2900
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Celltrion
Celltrion is a publicly listed company on the KRX with ticker symbol 068270 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Celltrion
Celltrion offers a comprehensive portfolio of products and services, including Biosimilars and R&D Services.
Biosimilars are developed and manufactured for various therapeutic areas such as immunology and oncology.
R&D services are provided for biopharmaceutical development, including clinical trials and regulatory affairs.
Funding Insights of Celltrion
Investors in Celltrion
Celltrion has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked |
Investor details for Celltrion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celltrion
Celltrion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include iQone Healthcare Group.
Investment portfolio details for Celltrion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of biosimilar and breakthrough medicines distribution
|
Locked | Locked | 1979 | Locked |
Complete acquisition details for Celltrion
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Celltrion
Detailed financials for Celltrion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celltrion Comparisons
Peer comparison for Celltrion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celltrion
Detailed competitors of Celltrion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celltrion
Complete news archive for Celltrion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celltrion
Celltrion was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Celltrion is headquartered in Incheon, South Korea.
Woo-Sung Kee is the current CEO of Celltrion.
As of Dec 31, 2024, the latest employee count at Celltrion is 2,900.
Annual revenue of Celltrion is $2.41B as on Dec 31, 2024.
Founded in 2002 in Incheon, South Korea, the company operates in the biotechnology sector, focusing on antibody biosimilars. Rensima, a biosimilar to infliximab, is utilized for treating rheumatoid arthritis and other autoimmune conditions. Additional biosimilars in development include versions of rituximab, adalimumab, bevacizumab, palivizumab, cetuximab, and etanercept. In 2020, annual revenues of 1.6 billion and net profit of 433.3 million were recorded.
Celltrion offers Biosimilars and R&D Services.
Yes, Celltrion is publicly traded on KRX under the ticker symbol 068270.
Celltrion has made 1 acquisition, including iQone Healthcare Group.
Celltrion has 1 investor. Key investors include Temasek.
The ticker symbol of Celltrion is 068270 on KRX.